Clinical Trials Browser

Active not recruiting × selinexor × Clear all

NCT06169215 2026-03-18

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04898894 2026-01-26

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT04216329 2026-01-23

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Phase 1 Active not recruiting

11 enrolled 19 charts

Glioblastoma, Gliosarcoma

NCT05954780 2026-01-14

SEATTLE

Active not recruiting

Multiple Myeloma

NCT04640779 2026-01-06

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT02091245 2025-12-02

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Phase 1 Active not recruiting

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04562389 2025-10-03

SENTRY

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03147885 2025-09-29

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07094464 2025-07-30

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04717700 2025-03-18

SABLe

Phase 2 Active not recruiting

Multiple Myeloma

NCT06452446 2025-02-10

Selinexor

Active not recruiting

Plasma cellSarcoma

Multiple Myeloma, Dendritic Cell Sarcoma, Interdigitating

NCT03555422 2025-01-20

ENGOT-EN5

Phase 3 Active not recruiting

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT04756401 2024-09-26

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma